Russell Investments Group’s Alaunos Therapeutics TCRT Stock Holding History

Russell Investments Group’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-524	Closed	-$282K	–	3293
2021 Q1	$282K	Buy	+524	New	+$326K	﹤0.01%	2740
2020 Q4	–	Sell	-554	Closed	-$209K	–	3187
2020 Q3	$209K	Buy	+554	New	+$245K	﹤0.01%	2763
2020 Q1	–	Sell	-177	Closed	-$125K	–	3132
2019 Q4	$125K	Hold	177	–	–	﹤0.01%	2839
2019 Q3	$114K	Buy	+177	New	+$140K	﹤0.01%	2798
2019 Q1	–	Sell	-860	Closed	-$241K	–	3009
2018 Q4	$241K	Sell	860 -160	-16%	-$63.3K	﹤0.01%	2554
2018 Q3	$490K	Sell	1,020 -529	-34%	-$227K	﹤0.01%	2398
2018 Q2	$702K	Hold	1,549	–	–	﹤0.01%	2287
2018 Q1	$911K	Buy	+1,549	New	+$965K	﹤0.01%	2242

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Russell Investments Group's TCRT Position: Q2 2021 in Review

Russell Investments Group sold out of Alaunos Therapeutics (TCRT) in Q2 2021, closing a stake of 524 shares — an estimated $282K sold.

Russell Investments Group first reported a position in TCRT in Q1 2018 and held it in 8 quarters. The position peaked at $911K in Q1 2018. 155 funds tracked by Wall St. Rank hold TCRT as of Q2 2021.

Russell Investments Group reported no remaining Alaunos Therapeutics position as of Q2 2021 after selling out during the quarter.
Russell Investments Group sold 524 Alaunos Therapeutics shares in Q2 2021, an estimated $282K.
Russell Investments Group first reported a position in Alaunos Therapeutics in Q1 2018 and held it in 8 quarters.
Russell Investments Group's Alaunos Therapeutics position peaked at $911K in Q1 2018.
155 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2021.

Based on Russell Investments Group's 13F filing for Q2 2021, filed 4 Aug 2021.